DOP2010000254A - Inhibidores del receptor de quimioquinas cxcr3 - Google Patents

Inhibidores del receptor de quimioquinas cxcr3

Info

Publication number
DOP2010000254A
DOP2010000254A DO2010000254A DO2010000254A DOP2010000254A DO P2010000254 A DOP2010000254 A DO P2010000254A DO 2010000254 A DO2010000254 A DO 2010000254A DO 2010000254 A DO2010000254 A DO 2010000254A DO P2010000254 A DOP2010000254 A DO P2010000254A
Authority
DO
Dominican Republic
Prior art keywords
cxcr3
chemiokin
inhibitors
receiver
benzosulfonamide
Prior art date
Application number
DO2010000254A
Other languages
English (en)
Inventor
David S Thorpe
Martin Smrcina
Dagmar D Cabel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of DOP2010000254A publication Critical patent/DOP2010000254A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

Esta invención se dirige a un compuesto 3-(amido o sulfamido)-4-(4-azinii sustituido)benzamida o benzosulfonamida como se define en la presente memoria. EI compuesto 3-(amido o sulfamido)-(4-azinil sustituido)benzamida o benzosulfonamida es útil como un inhibidor del receptor de quimioquinas CxCR3, y para prevenir o tratar una enfermedad mediada por el receptor de quimioquinas CxCR3 o afección relacionada con la misma en un paciente que lo necesite.
DO2010000254A 2008-02-19 2010-08-18 Inhibidores del receptor de quimioquinas cxcr3 DOP2010000254A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
DOP2010000254A true DOP2010000254A (es) 2010-08-31

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000254A DOP2010000254A (es) 2008-02-19 2010-08-18 Inhibidores del receptor de quimioquinas cxcr3

Country Status (25)

Country Link
US (1) US8268828B2 (es)
EP (1) EP2262784B1 (es)
JP (1) JP2011512412A (es)
KR (1) KR20100123835A (es)
CN (1) CN102007108A (es)
AR (1) AR070430A1 (es)
AU (1) AU2009215643A1 (es)
BR (1) BRPI0908815A2 (es)
CA (1) CA2715557A1 (es)
CL (1) CL2009000368A1 (es)
CO (1) CO6241113A2 (es)
CR (1) CR11604A (es)
DO (1) DOP2010000254A (es)
EC (1) ECSP10010409A (es)
IL (1) IL207597A0 (es)
MA (1) MA32191B1 (es)
MX (1) MX2010008397A (es)
NI (1) NI201000132A (es)
NZ (1) NZ587380A (es)
PE (1) PE20091576A1 (es)
RU (1) RU2010138577A (es)
SV (1) SV2010003648A (es)
TW (1) TW200948791A (es)
WO (1) WO2009105435A1 (es)
ZA (1) ZA201005314B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
JP5807971B2 (ja) 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
JP6162694B2 (ja) 2011-07-18 2017-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ベンズアミド類
EP2601950A1 (en) 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
CN104080784B (zh) * 2012-01-10 2017-07-18 默克专利有限公司 用作卵泡刺激素调节剂的苯甲酰胺衍生物
EA027595B1 (ru) 2012-02-02 2017-08-31 Актелион Фармасьютиклз Лтд. 4-(бензоимидазол-2-ил)тиазольные соединения и родственные азапроизводные
EP2666769A1 (en) 2012-05-23 2013-11-27 Sanofi Substituted B-amino acid derivatives as CXCR3 receptor antagonist
WO2015011099A1 (en) 2013-07-22 2015-01-29 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
CN107072205B (zh) * 2014-09-10 2022-07-15 Epizyme股份有限公司 Smyd抑制剂
UA119805C2 (uk) 2015-01-15 2019-08-12 Ідорсія Фармасьютікалз Лтд Похідні гідроксіалкілпіперазину як модулятори cxcr3-рецептора
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN110520127B (zh) 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2052541A5 (es) * 1969-06-13 1971-04-09 Takeda Chemical Industries Ltd
US3840556A (en) * 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
WO2003101970A1 (en) 2002-06-03 2003-12-11 Smithkline Beecham Corporation Imidazolium cxcr3 inhibitors
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
WO2006088921A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1856097B1 (en) * 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
US7417045B2 (en) * 2005-02-16 2008-08-26 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
WO2007002742A1 (en) * 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
WO2007047202A1 (en) 2005-10-11 2007-04-26 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
JP2009530383A (ja) 2006-03-21 2009-08-27 シェーリング コーポレイション Ｃｘｃｒ３拮抗活性を有する、新規ヘテロ環ピリジン置換体
CN101516869A (zh) 2006-07-14 2009-08-26 先灵公司 具有cxcr3拮抗剂活性的杂环取代的哌嗪化合物
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
NZ587380A (en) 2011-09-30
EP2262784A1 (en) 2010-12-22
ZA201005314B (en) 2011-03-30
SV2010003648A (es) 2011-01-31
TW200948791A (en) 2009-12-01
NI201000132A (es) 2011-03-16
RU2010138577A (ru) 2012-03-27
AU2009215643A1 (en) 2009-08-27
IL207597A0 (en) 2010-12-30
CA2715557A1 (en) 2009-08-27
PE20091576A1 (es) 2009-11-05
ECSP10010409A (es) 2010-09-30
MA32191B1 (fr) 2011-04-01
US20100305088A1 (en) 2010-12-02
MX2010008397A (es) 2010-08-23
CO6241113A2 (es) 2011-01-20
CN102007108A (zh) 2011-04-06
CL2009000368A1 (es) 2009-06-26
CR11604A (es) 2010-10-05
KR20100123835A (ko) 2010-11-25
WO2009105435A1 (en) 2009-08-27
AR070430A1 (es) 2010-04-07
EP2262784B1 (en) 2014-04-16
JP2011512412A (ja) 2011-04-21
US8268828B2 (en) 2012-09-18
BRPI0908815A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
DOP2010000254A (es) Inhibidores del receptor de quimioquinas cxcr3
CY1122778T1 (el) Μετεγχειρητικοι φραγμοι προσκολλησης
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
CU20140025A7 (es) Pirimidinas anilladas sustituidas
GT201400191A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
CR20110103A (es) Heteroarilos sustituidos
UY32110A (es) Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad
ECSP11010831A (es) Compuestos orgánicos para la cicatrización de heridas
UY32111A (es) Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
HN2012000973A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CR20110228A (es) Antagonistas del receptor de orexina de isonicotinamida
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
BRPI0813966A8 (pt) Usos de mdl-1
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
GT200600411A (es) Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
NI201000035A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR20110368A (es) Compuestos de quinazolina sustituidos
CR10111A (es) Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido
PA8782301A1 (es) Tratamiento de leucemia resistente al imatinte